Background: Inflammatory bowel disease (IBD) patients have a high incidence of wound and overall postoperative complications. A totally laparoscopic approach could potentially reduce these risks. We adopted totally laparoscopic total proctocolectomy (TL-TPC) using the perineal wound for extraction as the procedure of choice in IBD patients who are not candidates for a restorative procedure. This study looks at the TL-TPC results and compares them with our open cohort.
Methods: Prospectively collected data from 52 consecutive patients undergoing TL-TPC from 2002 to 2010 were compared to 31 contemporary patients undergoing open TPC.
Results: Demographics and patient characteristics including body mass index were similar. Mean operative times were 340 ± 7 minutes for TL-TPC and 337 ± 9 minutes for open TPC (P = 0.91). Intraoperative blood loss was 228 ± 2 mL for TL-TPC and 484 ± 3 mL for open TPC (P < 0.001). Return of bowel function measured as an ileostomy output >100 mL per 8 hours occurred at 2.7 ± 2.8 days for TL-TPC versus 3.3 ± 1.8 days for open TPC (P = 0.025). The length of stay was 8.4 ± 5.0 days for TL-TPC versus 9.2 ± 3.2 days for open TPC (P = 0.05). The overall complication rate was 43% for TL-TPC versus 65% for open TPC (P = 0.07). Postoperative abdominal wound infections and parastomal hernias occurred in 23% and 10% of open TPC patients, respectively, versus zero (P = 0.001) and 6% (P = 0.67) for TL-TPC.
Conclusions: TL-TPC is therefore considered a safe alternative to open surgery for selected IBD patients not candidates for a restorative procedure.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ibd.21808 | DOI Listing |
J Bronchology Interv Pulmonol
January 2025
Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School.
Background: Open window thoracostomy (OTW) is the standard of care for debilitated patients with chronic pleural infection and nonexpandable lungs (NEL) who are not candidates for major surgical intervention. Tunneled pleural catheters (TPC) offer tremendous treatment potential in this setting based on their efficacy in malignant pleural effusion and NEL. We aim to assess the efficacy, safety, and health care utilization of TPC in this setting.
View Article and Find Full Text PDFSmall
January 2025
Centre for Atomaterials and Nanomanufacturing (CAN), School of Science, RMIT University, Melbourne, VIC, 3000, Australia.
Due to the severe recombination of charge carriers, the photocatalytic activity of covalent organic frameworks (COFs) materials is limited. Herein, through simple ultrasound and stirring processes, the Pd metallene (Pde) is successfully combined with 2D COFs to form Pde/TpPa-1-COF (Pde/TPC) composites. Obviously, a strong internal electric field (IEF) is successfully formed in Pde/TPC hybrid materials, which significantly boosts the separation of photogenerated charges.
View Article and Find Full Text PDFInt J Biol Macromol
December 2024
Central South University of Forestry and Technology, Shaoshan South Road 498, Changsha 410004, China.
Two thermochromic poplar-based composites, TPC-1 and TPC-2, were fabricated using a crystal violet lactone (CVL)/lactic acid/myristyl alcohol ternary mixture. The mass ratios for TPC-1 and TPC-2 were 10: 3: 200 and 10: 80: 200, respectively. TPC-1 exhibits a common thermochromic property, reversibly changing color from blue to the natural hue of poplar within the temperature range of 28-48 °C.
View Article and Find Full Text PDFCommun Biol
September 2024
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
The continuous generation of multi-omics and phenotype data is propelling advancements in precision oncology. UCSCXenaShiny was developed as an interactive tool for exploring thousands of cancer datasets available on UCSC Xena. However, its capacity for comprehensive and personalized pan-cancer data analysis is being challenged by the growing demands.
View Article and Find Full Text PDFJ Gynecol Oncol
September 2024
Department of Gynecology, St. Mary's Hospital, Fukuoka, Japan.
Objective: To evaluate the long-term efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer.
Methods: This was the follow-up analysis of a phase 2, multicenter, open-label, single-arm study in Japanese women with homologous recombination-deficient, platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who had completed 3-4 lines of chemotherapy and were poly(ADP-ribose) polymerase inhibitor naïve. Participants received niraparib (starting dose, 300 mg) once daily in continuous 28-day cycles until objective disease progression, unacceptable toxicity, or consent withdrawal.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!